Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Neomorph, Inc
Bristol-Myers Squibb
City of Hope Medical Center
City of Hope Medical Center
University of Washington
M.D. Anderson Cancer Center
Allogene Therapeutics
NYU Langone Health
University of California, San Francisco